89bio, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is a glyco-engineered version of fibroblast growth factor 21 (FGF21) for the treatment of nonalcoholic steatohepatitis (NASH) and other liver and metabolic diseases. The company is headquartered in Philadelphia, Pennsylvania.